Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 3/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 4/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2723624 | 0.90 | MAPK1 (0.57) | MAPK1RXFP1GAANPSR1ALDH1A1 | |
| SCHEMBL1467161 | 0.86 | MAPK1 (0.65) | MAPK1GAANPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6200293 | 0.86 | MAPK1 (0.55) | MAPK1RXFP1GAANPSR1ALDH1A1 | |
| SCHEMBL401916 | 0.86 | MAPK1 (0.65) | MAPK1RXFP1GAANPSR1ALDH1A1 | |
| SCHEMBL439271 | 0.86 | MAPK1 (0.65) | MAPK1RXFP1GAANPSR1ALDH1A1 | |
| SCHEMBL11066821 | 0.85 | MEN1 (0.51) | MAPK1RXFP1GAANPSR1ALDH1A1 | |
| SCHEMBL1616605 | 0.84 | MAPK1 (0.53) | MAPK1RXFP1GAANPSR1ALDH1A1 | |
| SCHEMBL12850078 | 0.84 | MEN1 (0.50) | MAPK1RXFP1GAANPSR1ALDH1A1 | |
| SCHEMBL618410 | 0.84 | MAPT (0.62) | GAANPSR1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL10991178 | 0.84 | MEN1 (0.64) | MAPK1RXFP1GAANPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12172991-B2 | Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-12-24 | — | — | US | claimed |
| US-20210246128-A1 | BICYCLE TOPOISOMERASE I INHIBITING COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2021-08-12 | — | — | US | claimed |
| EP-3807248-A1 | BICYCLE TOPOISOMERASE I INHIBITING COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF | Council of Scientific and Industrial Research (IN) | 2021-04-21 | — | — | EP | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12492186-B2 | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| US-12486234-B2 | PAPD5 inhibitors and methods of use thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| CN-119798159-A | PAPD5 inhibitors and methods of use thereof | 儿童医学中心公司 | 2025-04-11 | — | — | CN | disclosed |
| US-12172991-B2 | Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-12-24 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| CN-114174279-B | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-4010317-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-1847226-A | Quinolyl amide derivative and its prepn process and use | INST OF TOXICANT PHARMACOLOGY (CN) | 2006-10-18 | — | — | CN | disclosed |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CHEN LI | 2006-03-23 | — | — | US | disclosed |
| WO-2006029861-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |
| WO-2004014384-A2 | CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014377-A1 | 4-HYDROXYQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-0793656-B1 | NOVEL BENZYL PYRIMIDINES | BASILEA PHARMACEUTICA AG (CH) | 2003-03-26 | — | — | EP | disclosed |
| US-5763450-A | BACTERICIDES; TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 1998-06-09 | — | — | US | disclosed |
| EP-0793656-A1 | NOVEL BENZYL PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016046-A2 | NOVEL BENZYL PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492186-B2 | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | MAPK1 372/4885RXFP1 1012/4885GAA 4744/4885 |
| US-12486234-B2 | PAPD5 inhibitors and methods of use thereof | POT1, PARP15, TERT | MAPK1 2772/4885RXFP1 3860/4885GAA 2529/4885 |
| US-12172991-B2 | Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof | TOP1, TOP2A, TOP2B | MAPK1 1850/4885RXFP1 4661/4885GAA 604/4885 |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CDK1, CDK14, CDK17 | MAPK1 640/4885RXFP1 4016/4885GAA 3945/4885 |
| US-20210246128-A1 | BICYCLE TOPOISOMERASE I INHIBITING COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF | TOP1, TOP2A, TOP2B | MAPK1 1850/4885RXFP1 4661/4885GAA 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.